First Patient Treated in Elixer Dynamx Coronary Bioadaptor Stent Technology

First Patient Treated in Elixer Dynamx Coronary Bioadaptor Stent Technology
International trial compares Bioadaptor coronary stent designed to adapt to vessel physiology with stanard DES
The Elixer Dynamx Coronary Bioadaptor Stent technology uses a bioresorbable polymer that dissolves after three months and disconnected joints between numerous stent segments, allowing it to articulate and shape to the vessel and its movement.
April, 14, 2021 – Elixir Medical recently announced the first patient was treated in the BIOADAPTOR randomized controlled trial (RCT) of the DynamX Coronary Bioadaptor System, the first drug-eluting coronary stent that adapts to vessel physiology. It uses a drug-eluting bioresorbable polymer coating that dissolves after three months, which disconnects joints between segments of the metallic stent, allowing it to articulate with vessel movement and its natural shape.

Related Keywords

Germany ,California ,United States ,Japan ,Kanagawa ,Fukushima ,Giessen ,Hessen ,Milpitas ,Motasim Sirhan ,Shigeru Saito ,Shonan Kamakura ,Elixir Medical Corporation ,Elixir Medical ,Dynamx Coronary Bioadaptor System ,Shonan Kamakura General Hospital ,Dynamx Bioadaptor ,Medtronic Resolute Onyx ,Holger Nef ,Elixer Dynamx Coronary Bioadaptor Stent ,Medical Corporation ,ஜெர்மனி ,கலிஃபோர்னியா ,ஒன்றுபட்டது மாநிலங்களில் ,ஜப்பான் ,கனகவா ,ஃபுகுஷிமா ,கிஎஸ்சென் ,ஹெஸன் ,மில்பிடாஸ் ,ஶிகேரு சைட்டோ ,ஷோனன் காமகுரா ,அமுதம் மருத்துவ நிறுவனம் ,அமுதம் மருத்துவ ,ஷோனன் காமகுரா ஜநரல் மருத்துவமனை ,மெதிடிறோனிக் உறுதியானது ஓனிக்ஸ் ,ஹோல்கர் நெப் ,மருத்துவ நிறுவனம் ,